UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): February 24, 2004



                           CHINDEX INTERNATIONAL, INC.
   -------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                    DELAWARE
                 ----------------------------------------------
                 (State or other jurisdiction of incorporation)

                 0-24624                              13-3097642
        --------------------------       ----------------------------------
        (Commission File Number)          (IRS Employer Identification No.)


                 7201 WISCONSIN AVENUE, BETHESDA, MARYLAND 20814
       -----------------------------------------------------------------
                    (Address of principal executive offices)


       Registrant's telephone number, including area code: (301) 215-7777


                                       NA
        -----------------------------------------------------------------
          (Former name or former address, if changed since last report)


<PAGE>

ITEM 12.  OTHER EVENTS AND REGULATION FD DISCLOSURE

      On February 24, 2004, the registrant announced revenue guidance in a press
release, a copy of which is attached hereto as Exhibit 99.1.

ITEM 7.  EXHIBITS

      Exhibit 99.1   Press Release dated February 24, 2004



                                    SIGNATURE


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                     CHINDEX INTERNATIONAL, INC.
                                     (Registrant)


          February 24, 2004          By:   /s/ LAWRENCE PEMBLE
       ----------------------           ----------------------------------------
               Date                        Lawrence Pemble
                                           Chief Financial Officer


<PAGE>

CHINDEX SUPPLEMENTS RECENT EARNINGS RELEASE
WITH REVENUE GUIDANCE

    BETHESDA, Maryland, February 24, 2004 --Chindex International, Inc.
(Nasdaq-CHDX) today supplemented its recent disclosure regarding results of
operations for the three- and nine-month periods ended December 31, 2003 and
provided indications of its expectations for revenue performance in the current
quarter and next fiscal year.

The Company advised that it expects that revenues for the fourth quarter ending
March 31, 2004 will be approximately the same level as the corresponding quarter
last year. Revenues for the current fiscal year have been negatively impacted by
the SARS epidemic and by delays in governmental negotiations of a framework
agreement for future loan programs that will be available to Chindex's
customers, which delays adversely affected the Company's Medical Capital
Equipment division.

The Company further advised that it expects revenues for its 2005 fiscal year
ending March 31, 2005 will increase substantially over revenues for the current
fiscal year and will return to profitability. The Company's expectations are
based on a number of factors, including its belief that the impact of SARS will
have been fully absorbed in the current fiscal year, loan programs will resume
and the Company's Shanghai United Family Hospital will open and commence revenue
generation. The Company noted that the expected increase in revenues for fiscal
2005 would be experienced in each of its three reporting segments and is
expected to be within a range of 25-35% on a consolidated basis. This revenue
increase would result in the Company exceeding $100 million for the first time
in its history.

The Healthcare Products Distribution division is projected to have a revenue
increase in fiscal 2005 of 20-30% with increased gross profit margins as new
higher-margin products are introduced in the retail pharmacy and hospital
products units in that division. These new products will improve the combined
gross profit margin in those units as they become an increasing percentage of
the product mix and as the Company reduces its focus on revenues from the
logistics business unit, which has experienced lower gross profit margins.

The Medical Capital Equipment division is projected to have a revenue increase
in fiscal 2005 of 20-30% and gross profit margins consistent with historical
levels. The Company believes that this increase will result principally from the
expansion of the Company's dealer networks, which increasingly supplement the
Company's traditional direct sales force, and from the resumption of
government-backed financings for its hospital customers .

The Healthcare Services division is projected to have a revenue increase in
fiscal 2005 of 50-60%. The Company expects that the division will report
increased profitability of its first hospital in Beijing, as it rebounds from

<PAGE>

the impact of SARS and realizes the benefit of the commencement of operations of
its new hospital in Shanghai, which is expected to open mid-2004.

This release includes forward-looking statements, which are based on the
Company's current expectations. Actual results could vary materially due to
changes in those expectations. These forward-looking statements involve known
and unknown risks, uncertainties and other factors (many of which are unable to
be predicted or controlled) that may cause the Company's actual results,
performance or achievements, or the healthcare products, capital medical
equipment or healthcare service industries' results, to be materially different
from those expressed or implied by the forward-looking statements. The
forward-looking statements contained in this announcement concerning revenues
and growth profit margins and actions that may be taken to improve financial
performance involve risks and uncertainties and are subject to change based on
various factors, including: the need to effectively manage growth; dependence on
key personnel; significantly variable timing of revenues and fluctuations in
financial performance not necessarily indicating longer-term performance; the
need for future financings for customer purchases and the uncertainty of
securing such financings; dependence on and concentration with suppliers with
terminable arrangements; increasing competition, including competition resulting
from China's membership in the WTO; the impact of SARS; dependence on qualified
sales representatives and service specialists; the need to maintain inventory;
the need for sophisticated data processing systems; the need for good relations
with Chinese foreign trade corporations; delays in the completion and opening of
the Shanghai United Family Hospital; the need to attract and retain qualified
physicians; the need to comply with heavy governmental regulation, including
each division and its market; the high cost of malpractice insurance of
physicians; the subjection to economic policies of the Chinese government and
the Chinese economy; the relatively undeveloped Chinese legal system; the impact
of inflation and/or foreign currency fluctuations; the risk of product liability
claims and/or product recalls; the dependence on information systems; the
dependence on sub-distributors and sub-dealers; the regulation by the Chinese
government of the conversion of Renminbi into foreign currency; the uncertainty
in the Company's markets for its products, including its healthcare products to
consumers, its medical capital equipment to hospitals and its healthcare
services in Beijing and Shanghai; and the need for additional capital, as to
which there can be no assurances as to availability. Given these uncertainties,
investors and prospective investors are cautioned not to rely on such
forward-looking statements. The Company disclaims any obligation, and makes no
promise, to update any such factors or forward-looking statements or to publicly
announce results of any revisions to any such forward-looking statements,
whether as a result of changes in underlying factors, to reflect new information
or as a result of the occurrence of events, developments or otherwise.